Cowen started coverage on shares of Applied Therapeutics (NASDAQ:APLT) in a research report sent to investors on Monday, BenzingaRatingsTable reports. The firm issued an outperform rating on the stock.

Several other equities research analysts also recently weighed in on APLT. UBS Group began coverage on shares of Applied Therapeutics in a research note on Monday. They issued a buy rating for the company. Robert W. Baird began coverage on shares of Applied Therapeutics in a research note on Monday. They issued an outperform rating and a $24.00 target price for the company.

Shares of APLT opened at $9.76 on Monday. Applied Therapeutics has a twelve month low of $7.95 and a twelve month high of $11.20.

In other news, Director Joel S. Marcus bought 150,000 shares of the stock in a transaction on Thursday, May 16th. The stock was bought at an average cost of $10.00 per share, for a total transaction of $1,500,000.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Shoshana Shendelman bought 125,000 shares of the stock in a transaction on Thursday, May 16th. The stock was purchased at an average price of $10.00 per share, with a total value of $1,250,000.00. The disclosure for this purchase can be found here. Over the last 90 days, insiders acquired 1,250,000 shares of company stock valued at $12,500,000.

Applied Therapeutics Company Profile

Applied Therapeutics, Inc, a biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-001 that is in phase II clinical trials for treating diabetic cardiomyopathy, as well as is in phase I clinical trials to treat diabetic peripheral neuropathy.

Recommended Story: What does an outperform rating mean?

Receive News & Ratings for Applied Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.